A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1613 participants.
Also called NCT05872620
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,613 participants
- Sponsor
- Registry
-
NCT05872620
-
- Other papers using this trial's data
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, Puerto Rico, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05872620. Randomized; double masking; primary purpose treatment. Start 2023-06-05 (actual); primary completion 2025-08-08 (actual). Results posted on 2026-09-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- Acronym
- ATTAIN-2
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05872620- Content hash
6bafff09c6466d6c7b36f447438a5f6fa42c052895140e7e5c3f016ba3547d12